eTurboNews - Independent and Global Travel, Tourism, Lifestyle, Entertainment News you only find here

Travel News Distribution powered by eTurboNews:

Frontier Pharma Pain-Identifying and Commercializing First-in-Class Innovation Market — Radiant Insights

(Forimmediaterelease.net) RadiantInsights.com has announced the addition of “Frontier Pharma Pain-Identifying and Commercializing First-in-Class Innovation” market research report to their database.
The active pain pipeline is populated by 796 products across all stages of development, which exhibit a highly diverse range of molecular targets. GBI Research’s analyses identified 122 first-in-class programs in active development, constituting 13.6% of the pipeline and acting on 65 first-in-class molecular targets, indicating a high degree of innovation. This is in stark contrast to the pain therapeutics market, which has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established active pharmaceutical ingredients and the concomitant mechanisms of action.

Browse full report here: www.radiantinsights.com/research/frontier-pharma-pain-identifying-and-commercializing-first-in-class-innovation

Moderate-to-severe pain continues to be dominated by opioids that are increasingly being reformulated to offer abuse-resistance, while mild pain is effectively treated with Non-Steroidal Anti-Inflammatory Drugs (NSAID). However, significant unmet needs remain, as chronic pain and some neuropathic pain subtypes do not respond well to existing therapies, which are not adequate to treat associated hypersensitization and do not align to the underlying molecular pathophysiological profile.

Despite being mostly distributed in the early stages of development, first-in-class innovation is particularly concentrated on novel molecular targets that are aligned to the central sensitization associated with neuropathic pain, which is arguably the most debilitating and difficult-to-treat type of chronic pain. This gives them the potential to transform the future market by expanding the range of drug classes.

In addition, GBI Research’s comprehensive and complementary analysis of granted patents highlighted a significant number of first-in-class product technologies, many of which have not been identified in the pain product pipelines or even in pipelines across the industry. The distribution of these products across the molecular target superfamilies and families highlighted that they predominantly align with the proportional distribution observed across the pain pipeline, with G-protein-coupled receptors and enzymes inhibitors constituting the two major categories. However, an array of novel molecular targets within those groups has been identified, which do not present in any pipeline or marketed products across the industry. A significant degree of innovation has also been identified in other molecular target categories.

To make avail the other sample reports, visit here:
www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare

However, an array of novel molecular targets within those groups has been identified, which do not present in any pipeline or marketed products across the industry. A significant degree of innovation has also been identified in other molecular target categories.

Latest Report by Radiant Insights:

Frontier Pharma: Antibiotics - Identifying and Commercializing First-in-Class Innovation:
www.radiantinsights.com/research/frontier-pharma-antibiotics-identifying-and-commercializing-first-in-class-innovation

The antibiotics pipeline is very active, with 741 products in development. Of these, the majority (85%) are at the Discovery or Preclinical stages and have not yet entered human trials. Such a high proportion of drugs at the earliest stages of development would, in other indications, provide hope of a steady stream of drugs due to advance through the stages of development and be approved within the next decade.

Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2015:
www.radiantinsights.com/research/interstitial-cystitis-pipeline-review-h1-2015


This report provides comprehensive information on the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Company Name: Radiant Insights, Inc. Contact Person: Michelle Thoras, Corporate Sales Specialist - USA Email: sales@radiantinsights.com Phone: (415) 349-0054, Toll Free: 1-888-202-9519 Address:28 2nd Street, Suite 3036 City: San Francisco State: Califonia Country: United States Website: www.radiantinsights.com/research/frontier-pharma-pain-identifying-and-commercializing-first-in-class-innovation

+++ Upload Your Press Release +++



Need assistance?

You need a little assistance?Call for help
+1-808-521-2800

Subscribe Now!

News Distribution Service

Distribute your press release with our service?

Submit Your Press-release

Latest Travel News


Top